CA2125985A1 - Stem cell inhibiting proteins - Google Patents

Stem cell inhibiting proteins

Info

Publication number
CA2125985A1
CA2125985A1 CA002125985A CA2125985A CA2125985A1 CA 2125985 A1 CA2125985 A1 CA 2125985A1 CA 002125985 A CA002125985 A CA 002125985A CA 2125985 A CA2125985 A CA 2125985A CA 2125985 A1 CA2125985 A1 CA 2125985A1
Authority
CA
Canada
Prior art keywords
stem cell
cell inhibiting
inhibiting proteins
dodecamer
mip
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002125985A
Other languages
French (fr)
Other versions
CA2125985C (en
Inventor
Stewart Craig
Michael G. Hunter
Richard M. Edwards
Lloyd G. Czaplewski
Richard J. Gilbert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vernalis R&D Ltd
Original Assignee
Stewart Craig
Michael G. Hunter
Richard M. Edwards
Lloyd G. Czaplewski
Richard J. Gilbert
British Bio-Technology Limited
British Biotech Pharmaceuticals Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919127319A external-priority patent/GB9127319D0/en
Priority claimed from GB929221587A external-priority patent/GB9221587D0/en
Application filed by Stewart Craig, Michael G. Hunter, Richard M. Edwards, Lloyd G. Czaplewski, Richard J. Gilbert, British Bio-Technology Limited, British Biotech Pharmaceuticals Limited filed Critical Stewart Craig
Publication of CA2125985A1 publication Critical patent/CA2125985A1/en
Application granted granted Critical
Publication of CA2125985C publication Critical patent/CA2125985C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Proteinaceous molecules with stem cell inhibition activity are analogues of or MIP-1.alpha. which have mutations to prevent or reduce multimer formation beyond certain stages (for example a dodecamer). Aggregate formation is therefore inhibited, and the resulting low molecular weight monomers (or oligomers) have improved solution properties leading to enhanced productivity and greater therapeutic utility as stem cell protective agents, which are useful in tumour therapy.
CA002125985A 1991-12-23 1992-12-23 Stem cell inhibiting proteins Expired - Fee Related CA2125985C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9127319.3 1991-12-23
GB919127319A GB9127319D0 (en) 1991-12-23 1991-12-23 Modified proteins
GB929221587A GB9221587D0 (en) 1992-10-14 1992-10-14 Modified proteins
GB9221587.0 1992-10-14
PCT/GB1992/002390 WO1993013206A1 (en) 1991-12-23 1992-12-23 Stem cell inhibiting proteins

Publications (2)

Publication Number Publication Date
CA2125985A1 true CA2125985A1 (en) 1993-07-08
CA2125985C CA2125985C (en) 2001-04-17

Family

ID=26300071

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002125985A Expired - Fee Related CA2125985C (en) 1991-12-23 1992-12-23 Stem cell inhibiting proteins

Country Status (10)

Country Link
US (2) US6057123A (en)
EP (1) EP0627003A1 (en)
JP (1) JPH07502404A (en)
AU (1) AU679436B2 (en)
CA (1) CA2125985C (en)
FI (1) FI943024A (en)
HU (2) HUT69788A (en)
NO (1) NO942380L (en)
NZ (1) NZ246354A (en)
WO (1) WO1993013206A1 (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9308060D0 (en) * 1993-04-19 1993-06-02 Cancer Res Campaign Tech Stem cell inhibitor
GB9312344D0 (en) * 1993-06-15 1993-07-28 British Bio Technology Pharmaceutical formulations
US5728377A (en) * 1993-07-20 1998-03-17 Board Of Regents, The University Of Texas System Methods and compositions incorporating IP-10
DE59410132D1 (en) * 1993-12-24 2002-07-11 Forssmann Wolf Georg HUMANESCIRCULAR CYTOKIN CC-1
GB9517014D0 (en) * 1995-08-19 1995-10-25 British Biotech Pharm Haematopoietic recovery
US5786335A (en) * 1995-11-06 1998-07-28 Warner-Lambert Company Sulfhydryl containing peptides for treating vascular disease
GB9600559D0 (en) * 1996-01-11 1996-03-13 British Biotech Pharm Use of chemokines
WO1998013495A1 (en) * 1996-09-25 1998-04-02 British Biotech Pharmaceuticals Limited Human rantes mutants incapable of aggregate formation
US6121023A (en) * 1998-01-22 2000-09-19 Akzo Nobel N.V. Isothermal transcription based assay for the detection and quantification of the chemokine rantes
CA2305787A1 (en) 2000-05-09 2001-11-09 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
AU762472B2 (en) 1998-03-13 2003-06-26 University Of British Columbia, The Therapeutic chemokine receptor antagonists
CA2245224A1 (en) 1998-08-14 2000-02-14 Jiang-Hong Giong Chemokine receptor antagonists and chemotherapeutics
US7368425B2 (en) 2006-03-24 2008-05-06 Chemokine Therapeutics Corp. Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis
CA2335109A1 (en) * 2000-04-12 2001-10-12 Chemokine Therapeutics Corporation Cxcr4 agonist treatment of hematopoietic cells
US7378098B2 (en) 2000-04-12 2008-05-27 The University Of British Columbia CXC chemokine receptor 4 agonist peptides
US20050059584A1 (en) 2002-08-16 2005-03-17 Ahmed Merzouk Novel chemokine mimetics synthesis and their use
US7311905B2 (en) * 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
ES2522890T3 (en) * 2000-12-06 2014-11-19 Anthrogenesis Corporation Method to collect placental stem cells
IL157350A0 (en) 2001-02-14 2004-02-19 Anthrogenesis Corp Post-partum mammalian placenta, its use and placental stem cells therefrom
US6515001B2 (en) 2001-03-05 2003-02-04 Chemokine Therapeutic Corporation IL-8 receptor ligands-drugs for inflammatory and autoimmune diseases
DE60231057D1 (en) 2001-12-17 2009-03-19 Serono Lab CHEMOKINE MUTANTS WORKING AS CHEMOKINE ANTAGONISTS
US7498171B2 (en) * 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
CN1668733A (en) * 2002-05-30 2005-09-14 细胞基因公司 Methods of using JNK or MKK inhibitors to modulate cell differentiation and to treat myeloproliferative disorders and myelodysplastic syndromes
JP2004196770A (en) * 2002-10-24 2004-07-15 Effector Cell Institute Inc Agent for increasing blood level of dendritic cell precursor
KR101042448B1 (en) 2002-11-26 2011-06-16 안트로제네시스 코포레이션 Cytotherapeutics, cytotherapeutic units and methods for treatments using them
CA2596232A1 (en) * 2005-01-31 2006-08-03 Effector Cell Institute The use of emip as cancer therapeutics in combination with electron beam irradiation or adjuvant treatment
EP1957633B1 (en) 2005-10-13 2013-12-18 Anthrogenesis Corporation Immunomodulation using placental stem cells
KR20080081088A (en) 2005-12-29 2008-09-05 안트로제네시스 코포레이션 Co-culture of placental stem cells and stem cells from a second source
CN103146640B (en) 2005-12-29 2015-09-09 人类起源公司 Placental stem cell populations
US7993918B2 (en) * 2006-08-04 2011-08-09 Anthrogenesis Corporation Tumor suppression using placental stem cells
NZ578819A (en) 2007-02-12 2012-02-24 Anthrogenesis Corp Treatment of inflammatory diseases using placental stem cells
TWM322542U (en) * 2007-05-23 2007-11-21 Universal Scient Ind Co Ltd Testing machine
US9200253B1 (en) 2007-08-06 2015-12-01 Anthrogenesis Corporation Method of producing erythrocytes
ES2530995T3 (en) 2007-09-28 2015-03-09 Anthrogenesis Corp Tumor suppression using human placental perfusate and intermediate natural killer cells that come from human placenta
DK2329012T3 (en) * 2008-08-20 2020-08-24 Celularity Inc Treatment of stroke using isolated placental cells
US10104880B2 (en) 2008-08-20 2018-10-23 Celularity, Inc. Cell composition and methods of making the same
MX339068B (en) 2008-08-22 2016-05-10 Anthrogenesis Corp Methods and compositions for treatment of bone defects with placental cell populations.
NZ602455A (en) 2008-11-19 2014-03-28 Anthrogenesis Corp Amnion derived adherent cells
AU2010266263B2 (en) * 2009-07-02 2016-05-19 Celularity Inc. Method of producing erythrocytes without feeder cells
US9121007B2 (en) 2010-01-26 2015-09-01 Anthrogenesis Corporatin Treatment of bone-related cancers using placental stem cells
KR20190076060A (en) 2010-04-07 2019-07-01 안트로제네시스 코포레이션 Angiogenesis using placental stem cells
US8562973B2 (en) 2010-04-08 2013-10-22 Anthrogenesis Corporation Treatment of sarcoidosis using placental stem cells
EP2593542B1 (en) 2010-07-13 2018-01-03 Anthrogenesis Corporation Methods of generating natural killer cells
AU2011352036A1 (en) 2010-12-31 2013-07-18 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory RNA molecules
US9040035B2 (en) 2011-06-01 2015-05-26 Anthrogenesis Corporation Treatment of pain using placental stem cells
US9925221B2 (en) 2011-09-09 2018-03-27 Celularity, Inc. Treatment of amyotrophic lateral sclerosis using placental stem cells
US9763983B2 (en) 2013-02-05 2017-09-19 Anthrogenesis Corporation Natural killer cells from placenta
KR20170123849A (en) * 2016-04-29 2017-11-09 주식회사유한양행 Fusion Protein Comprising CCL3 Variants And Use Thereof
US20210268070A1 (en) 2018-07-10 2021-09-02 Rush University Medical Center Use of Immunomodulators to Control Infection and Stimulate Healing in Normal and Diabetic Wounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929555A (en) * 1987-10-19 1990-05-29 Phillips Petroleum Company Pichia transformation
JPH05502443A (en) * 1989-09-25 1993-04-28 ジェネティックス・インスティテュート・インコーポレイテッド Stem cell growth inhibition method
JPH03228683A (en) * 1989-12-20 1991-10-09 Chemo Sero Therapeut Res Inst Bioactive peptide ld78alpha, ld78beta, production thereof and recombinant plasmid using same method
CA2091266A1 (en) * 1990-09-14 1992-03-15 Patricia Tekamp-Olson Expression of macrophage inducible proteins (mips) in yeast cells

Also Published As

Publication number Publication date
EP0627003A1 (en) 1994-12-07
NO942380L (en) 1994-08-23
HUT69788A (en) 1995-09-28
HU211605A9 (en) 1995-12-28
FI943024A0 (en) 1994-06-22
AU3260493A (en) 1993-07-28
FI943024A (en) 1994-06-22
JPH07502404A (en) 1995-03-16
US5856301A (en) 1999-01-05
US6057123A (en) 2000-05-02
AU679436B2 (en) 1997-07-03
NZ246354A (en) 1995-10-26
WO1993013206A1 (en) 1993-07-08
HU9401902D0 (en) 1994-09-28
NO942380D0 (en) 1994-06-22
CA2125985C (en) 2001-04-17

Similar Documents

Publication Publication Date Title
CA2125985A1 (en) Stem cell inhibiting proteins
CA2092533A1 (en) Nucleotide sequences coding for a human protein with angiogenesis regulative properties
NZ333373A (en) Use of amino acid derivatives for preparing compositions with improved multi-drug resistance activity
NO991951L (en) Tienopyrimidines with phosphodiesterase V inhibitory effect
CA2120303A1 (en) Cyclic adhesion inhibitors
EP1004595A3 (en) Lytic and proliferative peptides and their use as pharmaceutic and phytopharmaceutic agents
CA2172989A1 (en) Conotoxin peptides
EP1396542A3 (en) P-Selectin Ligand Protein
CA2100690A1 (en) Megakaryocyte differentiation factor
FI940375A0 (en) Peptides with organ protective effect, process for their preparation and their use in therapy
FI20075338A (en) No looping changes to gb350 / 220
AU1384995A (en) Human circulating cytokine cc-1
AU596388B2 (en) Peptides with sulfate ester groups
IL91184A0 (en) N-2,3-butadienyl tri-and tetraaminoalkane derivatives
NZ230654A (en) Anti-cell proliferative penta and hexa peptides
IE873084L (en) Peptides with sulfate ester groups
ES8707553A1 (en) Peptides.
CA2017315A1 (en) Interleukin i inhibitor
CA2043536A1 (en) Tumor cell growth inhibitor
RU93026009A (en) PRODUCT FROM MEAT MEAT
MX9205978A (en) NEW TOMB INHIBITOR PROTEINS OF TICKS.
Murakami et al. A cytocidal tissue kallikrein isolated from mouse submandibular glands
ES8800597A1 (en) Compositions containing 3-aminopropoxy-indoles for treating hypertension
CA2124937A1 (en) T-pa substitution variants with improved fibrin-specificity
ES2114170T3 (en) PEPTIDES WITH ORGAN-PROTECTIVE ACTIVITY, ITS PREPARATION PROCEDURE AND ITS USE IN THERAPY.

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed